Document is current
Any future updates will be listed below
-
Authors
Cao, Thinh-Phat https://orcid.org/0000-0001-9387-5460
Liao, Guan-Ru
Cheng, Tan-Yun
Chen, Yanqiong
Ciacchi, Laura https://orcid.org/0000-0002-9708-1526
Fulford, Thomas S. https://orcid.org/0000-0002-7210-5739
Farquhar, Rachel
Kollmorgen, Jade
Mayfield, Jacob A. https://orcid.org/0000-0002-5762-6755
Uldrich, Adam P. https://orcid.org/0000-0002-6350-5976
Ng, Emily Zhi Qing https://orcid.org/0009-0008-9491-6955
Ogg, Graham S. https://orcid.org/0000-0002-3097-045X
Godfrey, Dale I. https://orcid.org/0000-0002-3009-5472
Gherardin, Nicholas A. https://orcid.org/0000-0003-4690-2571
Chen, Yi-Ling https://orcid.org/0000-0003-3758-0638
Moody, D. Branch
Shahine, Adam https://orcid.org/0000-0001-7717-4437
Rossjohn, Jamie https://orcid.org/0000-0002-2020-7522
- License Information
-
More Information
Article History
Received: 7 August 2025
Accepted: 5 December 2025
First Online: 31 December 2025
Competing interests
: The authors have intellectual property though the Massachusetts General Brigham (D.B.M., G.S.O., J.R.) and the University of Oxford (G.S.O., Y.-L.C). G.S.O. and Y.-L.C. have relevant research collaborations with J&J Innovation. D.I.G. and N.A.G. hold PCT patents on therapeutic manipulation of CD1 family members. The remaining authors declare no competing interests.
